Edwards Lifesciences stockholders at the 2026 Annual Meeting elected all director nominees, approved executive compensation advisory proposal, auditor ratification, and amendment increasing Long-Term Stock Program shares by 7,000,000 to 341,500,000.
Key takeaways
Stockholders approved amendment to Long-Term Stock Program, adding 7,000,000 shares to total limit of 341,500,000.
All eight director nominees elected with For votes ranging 428.7M to 474.3M, against 1.3M to 45.4M.
Advisory vote on named executive officer compensation approved: 425M For vs 51M Against.
Ratification of PricewaterhouseCoopers LLP as auditor approved: 446M For vs 57M Against.
Broker non-votes consistent at 27.2M across all proposals.